Company / Working Capital
GeneDx Holdings Corp. Working Capital History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$159.4M
FY2025
5-year range
$68.3M / $382.3M
FY2021-FY2025
Trend
+11.3%
vs FY2024
Sector context
#129 of 165
Health Care
What the data says
GeneDx Holdings Corp.'s working capital of $159M is lower than 78% of companies in the Health Care sector (FY2025). Working Capital has increased for 3 consecutive years, from $68M in FY2022 to $159M in FY2025.
Based on SEC 10-K filings.
$159M in FY2025 with a 5-year CAGR of +9.6%.
Improved from $124M to $159M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +32.6%
- 5-Year CAGR
- +9.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 165This company $159.4M Sector average $836.2M
▼
-80.9% below sector average
Key checks
Key Insights
- GeneDx Holdings Corp.'s working capital has grown for 3 consecutive years.
- 5-year CAGR of +9.6%, indicating consistent growth.
- In FY2025, working capital increased 11.3% year-over-year.
- Ranks #129 out of 165 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- Negative profit margin: -17.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $159.4M | +11.3% |
| FY2024 | $143.2M | +15.9% |
| FY2023 | $123.5M | +80.8% |
| FY2022 | $68.3M | -82.1% |
| FY2021 | $382.3M | +279.7% |
| FY2020 | $100.7M | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026